Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Want to see CRBP full AI Analyst Report?
CRBP Stock Chart & Stats
$10.14
-$0.10(-0.79%)
At close: 4:00 PM EST
$10.14
-$0.10(-0.79%)
Day’s Range― - ―
52-Week Range$5.90 - $20.56
Previous CloseN/A
Volume39.58K
Average Volume (3M)503.64K
Market Cap
$177.36M
Enterprise Value$105.89M
Total Cash (Recent Filing)$163.94M
Total Debt (Recent Filing)$1.63M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
May 12, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding17,736,464
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.71
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$39.43Price Target Upside288.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.59
Revenue Forecast (FY)$2.00M
Bulls Say, Bears Say
Bulls Say
Drug Differentiation And DosingCRB-701's longer half-life and more stable linker could enable simpler dosing and potentially better effectiveness and safety compared with other nectin-4 targeted therapies.
Pipeline DiversificationEarly human data for CRB-913 showing meaningful weight reduction with favorable tolerability offers an additional commercial opportunity outside the oncology franchise.
Regulatory PathwayFDA alignment on a registrational trial design for CRB-701 that includes an accelerated approval pathway improves the likelihood of an expedited regulatory approval and clarifies the path to market.
Bears Say
Clinical Development UncertaintyLack of disclosed guidance on a pivotal cervical cancer trial together with ongoing regulatory discussions about study design and patient selection creates material uncertainty around the approval pathway.
Financial Runway RiskHigh cash burn and a limited cash runway may necessitate additional financing, which could lead to dilution and place downward pressure on the share price.
Pipeline PrioritizationRemoval of bladder and first-line treatment opportunities and deprioritization of other antibody programs narrow the development pipeline and reduce potential future revenue streams.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $5.90 and its highest was $20.56 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $177.36M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 24 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Mar 09, 2026. The company reported -$1.25 earnings per share for the quarter, beating the consensus estimate of -$1.518 by $0.268.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.22.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 17,736,464 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.25 in its last earnings report, beating expectations of -$1.518. Following the earnings report the stock price went up 19.226%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.43 (288.86% Upside)
$39.43 (288.86% Upside)
Hedge Fund Trend
Decreased
By 15.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $102.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.19%
12-Months-Change
Fundamentals
Return on Equity
-65.76%
Trailing 12-Months
Asset Growth
7.90%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP Stock 12 Month Forecast
Average Price Target
$39.43
▲(288.86% Upside)
Technical Analysis
Ownership Overview
15.81% Insiders
5.02% Mutual Funds
42.75% Other Institutional Investors
30.71% Public Companies and
Individual Investors